Triamcinolone acetonide aqueous intranasal - Sanofi

Drug Profile

Triamcinolone acetonide aqueous intranasal - Sanofi

Alternative Names: Nasacort; Nasacort AQ; Nasacort® Allergy 24HR Nasal Spray; Triamcinolone acetonide water-based intranasal - Sanofi

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 12 Jun 2015 Non-prescription aqueous intranasal triamcinolone acetonide licensed to PENDOPHARM for commercialisation in Canada
  • 11 Oct 2013 The US FDA approves Nasacort® as over-the-counter (OTC) product for treatment of Seasonal allergic rhinitis and Perennial allergic rhinitis in USA
  • 08 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top